Zheng Lin, Luo Mingjing, Zhou Haokui, Chen Jianping
Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Front Pharmacol. 2023 Jan 17;13:1068613. doi: 10.3389/fphar.2022.1068613. eCollection 2022.
Dysbiosis of gut microbiota plays a fundamental role in the pathogenesis and development of chronic kidney disease (CKD) and its complications. Natural products from plants and microorganisms can achieve recognizable improvement in renal function and serve as an alternative treatment for chronic kidney disease patients with a long history, yet less is known on its beneficial effects on kidney injury by targeting the intestinal microbiota. In this review, we summarize studies on the effects of natural products from plants and microorganisms, including herbal medicines and their bioactive extracts, polysaccharides from plants and microorganisms, and phytochemicals, on the prevention and treatment of chronic kidney disease through targeting gut microflora. We describe the strategies of these anti-CKD effects in animal experiments including remodulation of gut microbiota structure, reduction of uremic toxins, enhancement of short-chain fatty acid (SCFA) production, regulation of intestinal inflammatory signaling, and improvement in intestinal integrity. Meanwhile, the clinical trials of different natural products in chronic kidney disease clinical practice were also analyzed and discussed. These provide information to enable a better understanding of the renoprotective effects of these effective natural products from plants and microorganisms in the treatment of chronic kidney disease. Finally, we propose the steps to prove the causal role of the intestinal microflora in the treatment of chronic kidney disease by natural products from plants and microorganisms. We also assess the future perspective that natural active products from plants and microorganisms can beneficially delay the onset and progression of kidney disease by targeting the gut flora and highlight the remaining challenges in this area. With the continuous deepening of studies in recent years, it has been proved that gut microbiota is a potential target of natural active products derived from plants and microorganisms for chronic kidney disease treatment. Fully understanding the functions and mechanisms of gut microbiota in these natural active products from plants and microorganisms is conducive to their application as an alternative therapeutic in the treatment of chronic kidney disease.
肠道微生物群失调在慢性肾脏病(CKD)及其并发症的发病机制和发展中起重要作用。植物和微生物来源的天然产物可使肾功能得到显著改善,并可作为治疗慢性肾脏病的替代疗法,然而,其通过靶向肠道微生物群对肾脏损伤的有益作用却鲜为人知。在本综述中,我们总结了植物和微生物来源的天然产物,包括草药及其生物活性提取物、植物和微生物来源的多糖以及植物化学物质,通过靶向肠道微生物群预防和治疗慢性肾脏病的研究。我们描述了这些抗CKD作用在动物实验中的策略,包括重塑肠道微生物群结构、减少尿毒症毒素、增加短链脂肪酸(SCFA)生成、调节肠道炎症信号以及改善肠道完整性。同时,还分析和讨论了不同天然产物在慢性肾脏病临床实践中的临床试验。这些研究为更好地理解这些植物和微生物来源的有效天然产物在治疗慢性肾脏病中的肾脏保护作用提供了信息。最后,我们提出了证明肠道微生物群在植物和微生物来源的天然产物治疗慢性肾脏病中因果作用的步骤。我们还评估了植物和微生物来源的天然活性产物通过靶向肠道菌群有益地延缓肾脏疾病发生和进展的未来前景,并强调了该领域仍然存在的挑战。近年来随着研究的不断深入,已证明肠道微生物群是植物和微生物来源的天然活性产物治疗慢性肾脏病的潜在靶点。充分了解肠道微生物群在这些植物和微生物来源的天然活性产物中的功能和机制,有助于它们作为慢性肾脏病治疗的替代疗法应用。